Brentuximab vedotin-associated diabetic ketoacidosis: a case report
- PMID: 35875342
- PMCID: PMC9287688
- DOI: 10.1007/s13410-022-01116-w
Brentuximab vedotin-associated diabetic ketoacidosis: a case report
Abstract
Background: Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes mellitus (DM). It is characterized by hyperglycemia, metabolic acidosis, and ketonemia. Fortunately, drug-induced hyperglycemias are usually mild and not life-threatening. However, rarely some cases may present with ketoacidosis. In this case report, we aimed to present a brentuximab vedotin (BV) associated with DKA.
Case presentation: A 23-year-old Caucasian man presented with abdominal pain, nausea, and vomiting for 1-2 weeks. The patient had a previous diagnosis of Hodgkin's lymphoma and primer hypothyroidism. He is using levothyroxine 150 μg per day and received BV treatment for Hodgkin lymphoma (HL) 10 days ago. No steroid treatment was administered for premedication before BV. Except for obesity, all system examinations are normal. There were no signs of any infection. Laboratory data revealed hyperglycemia, metabolic acidosis, and ketonemia. The patient was admitted to the service with a diagnosis of DKA. After the patient was admitted to our clinic, insulin treatment and hydration started immediately. Despite the insulin infusion reaching 1700 units per day, the patient's diabetic ketoacidosis extended to 1 week. Anti-insulin, anti-glutamic acid decarboxylase, and islet cell autoantibodies were negative, which were checked to exclude type 1 DM. Fasting C-peptide was 28 ng/mL (normal range, 0.9-7.1 ng/mL). With all these, the diabetic ketoacidosis status of the patient was evaluated as a BV side effect.
Conclusion: This patient is a rare case of BV-associated DKA. It is very important to know this relationship since BV treatment has turned into a standard treatment for relapsed Hodgkin lymphoma. Our case highlights that this diagnosis should be kept in mind as a complication of each dose of BV administration.
Keywords: Brentuximab vedotin; Diabetic ketoacidosis; Drug-induced hyperglycemia.
© The Author(s), under exclusive licence to Research Society for Study of Diabetes in India 2022.
Conflict of interest statement
Competing interestsThe authors declare no competing interests.
Figures
Similar articles
-
Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin.Cureus. 2023 Mar 5;15(3):e35804. doi: 10.7759/cureus.35804. eCollection 2023 Mar. Cureus. 2023. PMID: 37025732 Free PMC article.
-
A new onset drug induced diabetes mellitus presenting with diabetic ketoacidosis in a child undergoing treatment for B cell acute lymphoblastic leukemia. A case report and review of literature.J Pediatr Endocrinol Metab. 2024 Jan 29;37(4):367-370. doi: 10.1515/jpem-2023-0443. Print 2024 Apr 25. J Pediatr Endocrinol Metab. 2024. PMID: 38281148 Review.
-
DIABETIC KETOACIDOSIS ASSOCIATED WITH ALPELISIB TREATMENT OF METASTATIC BREAST CANCER.AACE Clin Case Rep. 2020 Sep 24;6(6):e349-e351. doi: 10.4158/ACCR-2020-0452. eCollection 2020 Nov-Dec. AACE Clin Case Rep. 2020. PMID: 33244501 Free PMC article.
-
Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report.Clin Case Rep. 2021 Dec 5;9(12):e05144. doi: 10.1002/ccr3.5144. eCollection 2021 Dec. Clin Case Rep. 2021. PMID: 34917366 Free PMC article.
-
Brentuximab Vedotin Infusion Reaction Management: A Case Study.J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 1. J Adv Pract Oncol. 2017. PMID: 30310723 Free PMC article. Review.
Cited by
-
Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin.Cureus. 2023 Mar 5;15(3):e35804. doi: 10.7759/cureus.35804. eCollection 2023 Mar. Cureus. 2023. PMID: 37025732 Free PMC article.
-
Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin.BMJ Case Rep. 2024 Apr 2;17(4):e251867. doi: 10.1136/bcr-2022-251867. BMJ Case Rep. 2024. PMID: 38569738
-
Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases.PLoS One. 2025 May 16;20(5):e0322378. doi: 10.1371/journal.pone.0322378. eCollection 2025. PLoS One. 2025. PMID: 40378127 Free PMC article.
-
Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma.JCEM Case Rep. 2023 Nov 3;1(6):luad121. doi: 10.1210/jcemcr/luad121. eCollection 2023 Nov. JCEM Case Rep. 2023. PMID: 37942131 Free PMC article.
-
Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation-A Phase I Study.J Clin Med. 2022 Sep 13;11(18):5378. doi: 10.3390/jcm11185378. J Clin Med. 2022. PMID: 36143025 Free PMC article.
References
-
- Ansell SM. Hodgkin lymphoma: diagnosis and treatment. In: Mayo Clinic Proceedings. Elsevier Ltd; 2015. Hodgkin Lymphoma: Diagnosis and Treatment; pp. 1574–1583. - PubMed
-
- Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clinical Cancer Research. 2011;17:6428–36. 10.1158/1078-0432.CCR-11-0488 - PubMed
-
- Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21. 10.1056/NEJMoa1002965 - PubMed
Publication types
LinkOut - more resources
Full Text Sources